Furthermore, the cytokine interleukin‐1 (IL‐1) has emerged as a key therapeutic target in RA, with Cav‐1 playing a role in the vesicle‐mediated transport of the IL‐1 receptor [66]. Here, CAV1 is linked to rheumatoid arthritis.